Objective: To predict the global, regional, and national prevalence of Parkinson's disease by age, sex, year, and Socio-demographic Index to 2050 and quantify the factors driving changes in Parkinson's disease cases.

Design: Modelling study.

Data Source: Global Burden of Disease Study 2021.

Main Outcome Measures: Prevalent number, all age prevalence and age standardised prevalence of Parkinson's disease in 2050, and average annual percentage change of prevalence from 2021 to 2050; contribution of population ageing, population growth, and changes in prevalence to the growth in Parkinson's disease cases; population attributable fractions for modifiable factors.

Results: 25.2 (95% uncertainty interval 21.7 to 30.1) million people were projected to be living with Parkinson's disease worldwide in 2050, representing a 112% (95% uncertainty interval 71% to 152%) increase from 2021. Population ageing (89%) was predicted to be the primary contributor to the growth in cases from 2021 to 2050, followed by population growth (20%) and changes in prevalence (3%). The prevalence of Parkinson's disease was forecasted to be 267 (230 to 320) cases per 100 000 in 2050, indicating a significant increase of 76% (56% to 125%) from 2021, whereas the age standardised prevalence was predicted to be 216 (168 to 281) per 100 000, with an increase of 55% (50% to 60%) from 2021. Countries in the middle fifth of Socio-demographic Index were projected to have the highest percentage increase in the all age prevalence (144%, 87% to 183%) and age standardised prevalence (91%, 82% to 101%) of Parkinson's disease between 2021 and 2050. Among Global Burden of Disease regions, East Asia (10.9 (9.0 to 13.3) million) was projected to have the highest number of Parkinson's disease cases in 2050, with western Sub-Saharan Africa (292%, 266% to 362%) experiencing the most significant increase from 2021. The ≥80 years age group was projected to have the greatest increase in the number of Parkinson's disease cases (196%, 143% to 235%) from 2021 to 2050. The male-to-female ratios of age standardised prevalence of Parkinson's disease were projected to increase from 1.46 in 2021 to 1.64 in 2050 globally.

Conclusions: By 2050 Parkinson's disease will have become a greater public health challenge for patients, their families, care givers, communities, and society. The upward trend is expected to be more pronounced among countries with middle Socio-demographic Index, in the Global Burden of Disease East Asia region, and among men. This projection could serve as an aid in promoting health research, informing policy decisions, and allocating resources.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881235PMC
http://dx.doi.org/10.1136/bmj-2024-080952DOI Listing

Publication Analysis

Top Keywords

parkinson's disease
48
prevalence parkinson's
20
disease
16
global burden
16
burden disease
16
age standardised
16
standardised prevalence
16
2021 2050
16
parkinson's
12
0
12

Similar Publications

Objective: Gait disorder represents a characteristic symptom of Parkinson's disease (PD), and exercise has been established as an effective intervention for gait management in PD. However, the relative efficacy of various exercise types in improving gait among PD patients remains unclear. This study aimed to compare the effectiveness of different movement-based interventions in enhancing gait for individuals with PD through a network meta-analysis.

View Article and Find Full Text PDF

Background: The exact mechanisms of PD are unclear, but Parkin-mediated mitophagy dysfunction is believed to play a key role. We investigated whether blood levels of Parkin and other biomarkers are linked to the risk of developing PD.

Methods: Baseline blood measures of Parkin and other biomarkers, including Homocysteine, carcinoembryonic antigen, Urea, total proteins, total cholesterol, creatine kinase, and albumin, were collected from 197 clinically diagnosed Parkinson's disease participants and 107 age-matched healthy controls in Wenzhou Parkinson's Biomarkers and Living Characteristics study.

View Article and Find Full Text PDF

Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder, after Alzheimer's disease. Many individuals with PD experience cognitive impairment, significantly threatening both their physical and mental well-being. Research has shown that abnormal DNA methylation is closely linked to neurodegenerative conditions such as Alzheimer's and Parkinson's disease.

View Article and Find Full Text PDF

Chronic pain affects a significant portion of adults and is linked to psychosocial issues, cognitive dysfunction, and psychiatric disorders, complicating treatment. Attention deficit hyperactivity disorder (ADHD) is increasingly recognized as a contributing factor to chronic pain, particularly nociplastic pain, with a notable prevalence of comorbidity between ADHD and conditions like fibromyalgia and chronic low back pain. ADHD behaviors such as impulsivity and overactivity can exacerbate pain by leading patients to seek risky treatments or discontinue care prematurely.

View Article and Find Full Text PDF

Introduction: Tobacco use is as a major public health concern around the world, adversely impacting quality of life. Our study aims to analyze the trends in the burden of tobacco-related neurological disorders (ND) at global, regional, and national levels from 1990 to 2021, as well as potential future trends.

Methods: We performed a secondary dataset analysis for the assessment of mortality and disability-adjusted life years (DALYs) using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, to explore the burden of tobacco-related ND.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!